View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 19, 2020

Chinese Covid-19 vaccine shows promising results in Phase I/II trial

A potential Covid-19 vaccine being developed by China National Biotech Group (CNBG) unit Beijing Institute of Biologic Products demonstrated to be safe and triggered immune responses in a combined early and mid-stage test in humans, according to researchers.

A potential Covid-19 vaccine being developed by China National Biotech Group (CNBG) unit Beijing Institute of Biologic Products demonstrated to be safe and triggered immune responses in a combined early and mid-stage test in humans, according to researchers.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

Dubbed BBIBP-CorV, the vaccine is already approved for an emergency inoculation programme in China targeting essential workers and others at high infection risk.

According to the World Health Organization (WHO), BBIBP-CorV is one of at least ten coronavirus vaccine programmes progressed to Phase III trials worldwide, with four among these led by Chinese scientists.

The dose-escalation, randomised, double-blind, placebo-controlled, Phase I / II trial of BBIBP-CorV enrolled over 600 healthy participants aged between 18 and 80 years.

The Covid-19 vaccine trial was conducted between 29 April and 30 July in a single centre in China.

Data from the trials showed that giving two injections of BBIBP-CorV at three different doses was safe and well-tolerated in all participants.

Throughout the trial, a robust humoral immune response was observed in all vaccine recipients.

In participants aged 60 and above, antibody levels were lower and took longer to increase significantly than those in younger recipients.

The results do not prove the vaccine is efficacious, a paper published in the medical journal the Lancet showed.

No severe side effects were observed but common mild or moderate adverse reactions such as fever and pain in injection sites were noted.

The study claimed no notable changes in lymphocyte subset or cytokines. The Phase III trials of BBIBP-CorV are progressing outside china.

Aside from this study, state-owned China National Pharmaceutical Group (Sinopharm) unit CNBG has a similar candidate, which is in Phase III trials outside China and used in the country’s emergency use programme.

This investigational candidate induced antibodies without developing serious side effects in early and mid-stage trials.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena